BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced positive preclinical data further detailing the mechanism of action and potential therapeutic use of selective HDAC1/2 inhibitors in the treatment of sickle cell disease (SCD) and beta-thalassemia (bT). The data were presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition in San Francisco, California.
Help employers find you! Check out all the jobs and post your resume.
